Venetoclax is a BCL2-inhibitor with no direct cardiotoxic effects which has demonstrated high efficacy when combined with obinutuzumab for CLL [24] or as a monotherapy for Waldenström's [25]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.